Sabrina Martucci Johnson - 26 Jun 2025 Form 4 Insider Report for ATAI Life Sciences N.V. (ATAI)

Reporting relationship
Director
Issuer ticker
ATAI
Reported as of
26 Jun 2025
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
27 Jun 2025, 17:31:27 UTC
Prior SEC filing
31 Jan 2025
Next SEC filing
02 Feb 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Ryan Barrett, Attorney-in-fact

Key filing fact

Sabrina Martucci Johnson filed Form 4 for ATAI Life Sciences N.V. (ATAI) on 27 Jun 2025.

Key facts

  • This page summarizes Sabrina Martucci Johnson's Form 4 filing for ATAI Life Sciences N.V. (ATAI).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 27 Jun 2025, 17:31.

Change

  • Previous filing in this sequence was filed on 31 Jan 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001199102 Primary reporting owner

JOHNSON SABRINA MARTUCCI

Relationship
Director
Address
C/O ATAI LIFE SCIENCES N.V., PROF. J.H. BAVINCKLAAN 7, AMSTERDAM, NETHERLANDS
Signature
/s/ Ryan Barrett, Attorney-in-fact
Signature date
27 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATAI transaction Derivative

Stock Option

Award

Transaction value
$0
Shares
+103,000
Change %
Price
$0.000000
Shares after
103,000
Date
26 Jun 2025
Ownership
Direct
Underlying class
Common Shares
Underlying amount
103,000
Exercise price
$2.25
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or June 26, 2026.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .